The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation

• Published in: BMC cancer 2019-05, Vol.19 (1), p.455-455, Article 455
• Main Authors: Kojima, Machiko, Sone, Kenbun, Oda, Katsutoshi, Hamamoto, Ryuji, Kaneko, Syuzo, Oki, Shinya, Kukita, Asako, Machino, Hidenori, Honjoh, Harunori, Kawata, Yoshiko, Kashiyama, Tomoko, Asada, Kayo, Tanikawa, Michihiro, Mori-Uchino, Mayuyo, Tsuruga, Tetsushi, Nagasaka, Kazunori, Matsumoto, Yoko, Wada-Hiraike, Osamu, Osuga, Yutaka, Fujii, Tomoyuki
• Format: Article
• Language: English
• Subjects: Analysis; Apoptosis; Cancer research; Carcinoma; Care and treatment; Cell cycle; Cell growth; Cell proliferation; Chemotherapy; Endometrial cancer; Enhancer of zeste homolog 2; Epigenetic inheritance; Epigenetic modifier; EZH2 selective inhibitor, H3K36 dimethylation, cell proliferation; Flow cytometry; Gene expression; Genes; Genetic aspects; Histone methyltransferase; Histone methyltransferase, Wolf-Hirschhorn syndrome candidate gene-1; Histones; Immunoblotting; Immunohistochemistry; Kinases; Lymphoma; Medical research; Methyltransferases; Mutation; Ovarian cancer; Ovarian clear cell carcinoma; Polymerase chain reaction; siRNA; Therapeutic applications; Transferases
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-019-5638-9

Wolf-Hirschhorn syndrome candidate gene-1 (WHSC1), a histone methyltransferase, has been found to be upregulated and its expression to be correlated with expression of enhancer of zeste homolog 2 (EZH2) in several cancers. In this study, we evaluated the role of WHSC1 and its therapeutic significance in ovarian clear cell carcinoma (OCCC). First, we analyzed WHSC1 expression by quantitative PCR and immunohistochemistry using 23 clinical OCCC specimens. Second, the involvement of WHSC1 in OCCC cell proliferation was evaluated by MTT assays after siRNA-mediated WHSC1 knockdown. We also performed flow cytometry (FACS) to address the effect of WHSC1 on cell cycle. To examine the functional relationship between EZH2 and WHSC1, we knocked down EZH2 using siRNAs and checked the expression levels of WHSC1 and its histone mark H3K36m2 in OCCC cell lines. Finally, we checked WHSC1 expression after treatment with the selective inhibitor, GSK126. Both quantitative PCR and immunohistochemical analysis revealed that WHSC1 was significantly overexpressed in OCCC tissues compared with that in normal ovarian tissues. MTT assay revealed that knockdown of WHSC1 suppressed cell proliferation, and H3K36me2 levels were found to be decreased in immunoblotting. FACS revealed that WHSC1 knockdown affected the cell cycle. We also confirmed that WHSC1 expression was suppressed by EZH2 knockdown or inhibition, indicating that EZH2 is upstream of WHSC1 in OCCC cells. WHSC1 overexpression induced cell growth and its expression is, at least in part, regulated by EZH2. Further functional analysis will reveal whether WHSC1 is a promising therapeutic target for OCCC.